Morningstar Investment Services LLC raised its holdings in Sanofi (NYSE:SNY) by 7.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 733,038 shares of the company’s stock after acquiring an additional 52,709 shares during the quarter. Morningstar Investment Services LLC’s holdings in Sanofi were worth $36,498,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Fisher Asset Management LLC boosted its position in shares of Sanofi by 3.3% during the third quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock worth $701,156,000 after purchasing an additional 443,799 shares in the last quarter. Boston Partners boosted its position in shares of Sanofi by 6.2% during the third quarter. Boston Partners now owns 8,664,983 shares of the company’s stock worth $431,429,000 after purchasing an additional 503,799 shares in the last quarter. FMR LLC boosted its position in shares of Sanofi by 3.0% during the second quarter. FMR LLC now owns 5,374,385 shares of the company’s stock worth $257,487,000 after purchasing an additional 155,751 shares in the last quarter. Macquarie Group Ltd. lifted its position in Sanofi by 1.1% in the 3rd quarter. Macquarie Group Ltd. now owns 2,622,391 shares of the company’s stock valued at $130,569,000 after acquiring an additional 29,045 shares in the last quarter. Finally, BlackRock Inc. lifted its position in Sanofi by 47.6% in the 2nd quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock valued at $107,100,000 after acquiring an additional 720,523 shares in the last quarter. 9.30% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts recently commented on SNY shares. Cowen and Company reaffirmed a “market perform” rating and issued a $52.00 price objective (up from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. BidaskClub raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. raised shares of Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Argus reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a research report on Friday, September 1st. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $53.50.

Shares of Sanofi (SNY) traded up $0.58 during mid-day trading on Thursday, reaching $45.37. 968,700 shares of the company’s stock traded hands, compared to its average volume of 1,510,858. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. Sanofi has a 12-month low of $38.45 and a 12-month high of $50.65. The firm has a market cap of $112,938.35, a price-to-earnings ratio of 14.13, a P/E/G ratio of 2.47 and a beta of 0.88.

COPYRIGHT VIOLATION NOTICE: “Morningstar Investment Services LLC Acquires 52,709 Shares of Sanofi (SNY)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/11/23/morningstar-investment-services-llc-acquires-52709-shares-of-sanofi-sny.html.

Sanofi Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.